Table 3 Patient demographics for the validation cohort.

From: A novel biomarker of MMP-cleaved cartilage intermediate layer protein-1 is elevated in patients with rheumatoid arthritis, ankylosing spondylitis and osteoarthritis

 

Healthy (N = 105)

Rheumatoid arthritis (N = 23)

Ankylosing spondylitis (N = 146)

p-value

Age (years)

41.23 (12.69)

57.78 (10.94)

44.36 (12.67)

< 0.001

Sex (male)

53 (52.0%)

18 (78.3%)

113 (77.4%)

< 0.001

Disease duration (years)

–

13.45 (11.26)

20.92 (13.72)

 

Anti-TNF-α

 Etanercept

–

14 (60.9%)

27 (85.6%)

 

 Adalimumab

–

–

18 (12.3%)

 Infliximab

–

9 (39.1%)

44 (30.1%)

 Golimumab

–

–

8 (5.5%)

 No (NSAIDs)

–

–

49 (33.56%)

Baseline CRP (mg/L)

–

26.93 (38.86)

14.69 (20.24)

 

Baseline ESR (mm/h)

–

34.73 (27.00)

21.50 (19.19)

 

Baseline BASDAI

–

–

5.58 (2.36)

 

Baseline mSASSS

–

–

17.09 (19.60)

 

2 years follow-up mSASS

  

19.84 (21.13)

 

Patients with change (> 0) in mSASSS at 2 years follow-up

  

100(68%)

 

CILP-M (ng/mL)

1.06 (0.57)

2.78 (1.87)

2.45 (1.03)

< 0.001

  1. Categorical variables are written as number (percentage), while continuous variables are mean (standard deviation). Kruskal–Wallis rank test was used to compare differences among the groups.
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, mSASSS modified Stoke Ankylosing Spondylitis Spinal Score.
Back to article page